[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100647695":3},{"organization":4,"armGroups":7,"interventions":27,"overallOfficials":37,"centralContacts":41,"locations":46,"responsibleParty":61,"collaborators":33,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":33,"eligibilityCriteria":69,"healthyVolunteers":70,"sex":71,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":33,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":49,"whyStopped":33,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"BeOne Medicines","INDUSTRY",[8,15,19,23],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment Sequence 1","EXPERIMENTAL","Participants will receive a single oral dose of BGB-58067 F-01 tablet in fasted state, BGB-58067 F-02 tablet in fasted state, BGB-58067 F-02 tablet in the fed state with a high fat meal, and BGB-58067 F-02 tablet in the fed state with a low fat meal, with a 7-day washout between each dose.",[13,14],"Drug: BGB-58067 Tablet (F-01 Formulation)","Drug: BGB-58067 Tablet (F-02 Formulation)",{"label":16,"type":10,"description":17,"interventionNames":18},"Treatment Sequence 2","Participants will receive a single oral dose of BGB-58067 F-02 tablet in fasted state, BGB-58067 F-02 tablet in the fed state with a low fat meal, BGB-58067 F-01 tablet in fasted state, and BGB-58067 F-02 tablet in the fed state with a high fat meal, with a 7-day washout between each dose.",[13,14],{"label":20,"type":10,"description":21,"interventionNames":22},"Treatment Sequence 3","Participants will receive a single oral dose of BGB-58067 F-02 tablet in fed state with low-fat meal, F-02 tablet in the fed state with a high fat meal, BGB-58067 F-02 tablet in fasted state, and BGB-58067 F-01 tablet in fasted state, with a 7-day washout between each dose.",[13,14],{"label":24,"type":10,"description":25,"interventionNames":26},"Treatment Sequence 4","Participants will receive a single oral dose of BGB-58067 F-02 tablet in fed state with high-fat meal, BGB-58067 F-01 tablet in fasted state, BGB-58067 F-02 tablet in the fed state with a low fat meal, and BGB-58067 F-02 tablet in fasted state, with a 7-day washout between each dose.",[13,14],[28,34],{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"DRUG","BGB-58067 Tablet (F-01 Formulation)","Administered orally",[9,16,20,24],null,{"type":29,"name":35,"description":31,"armGroupLabels":36,"otherNames":33},"BGB-58067 Tablet (F-02 Formulation)",[9,16,20,24],[38],{"name":39,"affiliation":5,"role":40},"Study Director","STUDY_DIRECTOR",[42],{"name":39,"role":43,"phone":44,"phoneExt":33,"email":45},"CONTACT","1-877-828-5568","clinicaltrials@beonemed.com",[47],{"facility":48,"status":49,"city":50,"state":51,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":33},"Cmax Clinical Research","RECRUITING","Adelaide","South Australia","SA 5000","Australia","AU",{"type":56,"coordinates":57},"Point",[58,59],138.59863,-34.92866,{"lat":59,"lon":58},{"type":62,"investigatorFullName":33,"investigatorTitle":33,"investigatorAffiliation":33,"oldNameTitle":33,"oldOrganization":33},"SPONSOR","100647695","a-study-to-investigate-the-relative-bioavailability-of-2-tablet-formulations-and-the-effect-of-food-on-the-pharmacokinetics-of-bgb-58067-in-healthy-participants-100647695",false,"NCT07712640","A Study to Investigate the Relative Bioavailability of 2 Tablet Formulations and the Effect of Food on the Pharmacokinetics of BGB-58067 in Healthy Participants","A Phase 1, Single Dose, Open-label, Randomized 4-Period, 4-Sequence Crossover Study to Assess the Relative Bioavailability of Two Tablet Formulations of BGB-58067 and the Effect of Food on the Pharmacokinetics of a Single Oral Dose of BGB-58067 Administered Simultaneously to Healthy Adult Participants","Inclusion Criteria:\n\n* Participants must be 18 to 65 years of age, inclusive, at the time of signing the ICF.\n* Participants who are overtly healthy, as determined by the investigator or delegate through medical evaluation\n* Female participants must be of non-childbearing potential. Note: A woman is considered childbearing potential (ie, fertile, following menarche and until becoming postmenopausal) unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy, and bilateral oophorectomy\n* Nonsterile male participants must be willing to use condom and refrain from sperm donation for the duration of the study and for 90 days after the last dose of BGB-58067.An additional highly effective method of birth control must be used for the duration of the study and for 90 days after the last dose of BGB-58067. A sterile man is defined as one for whom azoospermia has been previously demonstrated in a semen sample examination as definitive evidence of infertility. Men with known \"low sperm counts\" (consistent with \"subfertility\") are not to be considered sterile for purposes of this study\n\nExclusion Criteria:\n\n* Presence or history of relevant seasonal allergies requiring treatment, drug and\u002For food allergies (ie, allergy to any study drug or excipients, or any significant food allergy that could preclude a standard diet in the study site). Hay fever is allowed unless it is active (ie, No clinically meaningful allergy symptoms at screening and pre-dose, no requirement for pharmacologic therapy, and stable condition without anticipated flare during the PK assessment period).\n* History of clinically significant cardiovascular, hematological, renal, hepatic, chronic respiratory or gastrointestinal disease, neurological or psychiatric (including SIB) disorder, or severe cutaneous adverse reactions such as Stevens-Johnson Syndrome, as judged by the investigator or delegate.\n* Participants with a history of cholecystectomy or gall stones.\n\nNote: Other protocol-defined inclusion\u002Fexclusion criteria may apply.",true,"ALL","18 Years","65 Years",{"count":75,"type":76},32,"ESTIMATED","INTERVENTIONAL",[79],"PHASE1","This study is being done to understand how the body processes 2 different tablet formulations of the study drug (BGB-58067) and how food intake influences the processing of the study drug by the body.",[82],"Healthy Volunteers",[84,85,86,87],"Relative bioavailability","Food effect","Tablets formulation","Healthy volunteer","2026-08-06",{"date":90,"type":91},"2026-08-10","ACTUAL",{"date":93,"type":91},"2026-07-21",{"date":95,"type":76},"2028-07-01",{"name":5,"class":6},1]